Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725204 | 0.96 | AGXT (0.48) | AGXTKCNH2CA1CA2CA9 | |
| SCHEMBL12783816 | 0.94 | AGXT (0.47) | AGXTKCNH2CA1CA2CA9 | |
| SCHEMBL9861794 | 0.88 | AGXT (0.58) | AGXTKCNH2CA1CA2CA9 | |
| SCHEMBL3161372 | 0.83 | AGXT (0.64) | AGXTKCNH2CA1CA2CA9 | |
| SCHEMBL9617939 | 0.83 | AGXT (0.64) | AGXTKCNH2CA1CA2CA9 | |
| SCHEMBL15452321 | 0.82 | IDO1 (0.48) | CA2IDO1TAAR1 | |
| SCHEMBL15096867 | 0.82 | ALDH1A1 (0.39) | AGXTKCNH2CA1CA2IDO1 | |
| SCHEMBL12378 | 0.80 | AGXT (0.61) | AGXTKCNH2CA1CA2CA9 | |
| Lithium SCHEMBL585057 | 0.80 | AGXT (0.61) | AGXTKCNH2CA1CA2CA9 | |
| Potassium SCHEMBL586332 | 0.80 | AGXT (0.61) | AGXTKCNH2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202372-B2 | Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2019-02-12 | — | — | US | disclosed |
| EP-2885297-B1 | TRISUBSTITUTED PYRIDO[3,2-D]PYRIMIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTICAL USES | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-10-11 | — | — | EP | disclosed |
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | UNIVERSITE D'ORLEANS (FR) | 2015-07-23 | — | — | US | disclosed |
| US-20130184462-A1 | METHOD FOR PREDICTING AND MODELING ANTI-PSYCHOTIC ACTIVITY USING VIRTUAL SCREENING MODEL | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | DPYD, TYMP, RRM2B | AGXT 3299/4885KCNH2 2405/4885CA1 3440/4885 |
| US-10202372-B2 | Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof | DPYD, TYMP, RRM2B | AGXT 3299/4885KCNH2 2405/4885CA1 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.